These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24828964)

  • 21. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How psychiatrists inform themselves and their patients about risks and benefits of antipsychotic treatment.
    Mendel R; Hamann J; Traut-Mattausch E; Jonas E; Heres S; Frey D; Kissling W
    Acta Psychiatr Scand; 2009 Aug; 120(2):112-9. PubMed ID: 19236315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Influence of Genotype Information on Psychiatrists' Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore.
    McMichael AJ; Boeri M; Rolison JJ; Kane J; O'Neill FA; Scarpa R; Kee F
    Value Health; 2017 Jan; 20(1):126-131. PubMed ID: 28212953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PRESCRIPTION PATTERNS IN THE TREATMENT OF SCHIZOPHRENIA].
    Leiderman EA; Lorenzo L
    Vertex; 2015; 26(119):11-6. PubMed ID: 26323108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders.
    Hamann J; Lipp ML; Christ-Zapp S; Spellmann I; Kissling W
    Psychiatr Serv; 2014 Jul; 65(7):881-7. PubMed ID: 24686753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey.
    Kurokawa S; Kishimoto T; Su KP; Chang JP; Chang HC; Yu X; Rodrigues-Silva N; Nielsen J; Unadkat A; Castle D; Haddad PM; Rocha D; Gadelha A; Kaliora S; Petrides G; Agid O; Tazawa Y; Takamiya A; Horigome T; Kane JM
    Schizophr Res; 2019 Sep; 211():105-107. PubMed ID: 31371039
    [No Abstract]   [Full Text] [Related]  

  • 27. Addressing side effects from antipsychotic treatment in schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Feb; 72(2):e07. PubMed ID: 21382302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa.
    Olivares JM; Alptekin K; Azorin JM; Cañas F; Dubois V; Emsley R; Gorwood P; Haddad PM; Naber D; Papageorgiou G; Roca M; Thomas P; Martinez G; Schreiner A
    Patient Prefer Adherence; 2013; 7():121-32. PubMed ID: 23390361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survey of medication adherence in patients with schizophrenia--Korean ADHES data.
    Kim SW; Yoon JS; Choi SK
    Hum Psychopharmacol; 2006 Dec; 21(8):533-7. PubMed ID: 17133616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia.
    Montes JM; Medina E; Gomez-Beneyto M; Maurino J
    Psychiatry Res; 2012 Dec; 200(2-3):89-95. PubMed ID: 22901437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Significance of psychiatrists' personal variables in treatment of persons suffering from schizophrenia].
    Sawicka M; Charzyńska K
    Psychiatr Pol; 2014; 48(6):1213-23. PubMed ID: 25717490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.
    McIntyre RS
    J Clin Psychiatry; 2009; 70 Suppl 3():5-11. PubMed ID: 19570496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychiatrists' perceptions of potential reasons for non- and partial adherence to medication: results of a survey in bipolar disorder from eight European countries.
    Vieta E; Azorin JM; Bauer M; Frangou S; Perugi G; Martinez G; Schreiner A
    J Affect Disord; 2012 Dec; 143(1-3):125-30. PubMed ID: 22840608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey.
    Olivares JM; Thirunavukarasu M; Kulkarni J; Zhang HY; Zhang M; Zhang F
    Neuropsychiatr Dis Treat; 2013; 9():1163-70. PubMed ID: 23976858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.